{
  "drug_name": "Desmopressin",
  "url": "https://wikem.org/wiki/Desmopressin",
  "scraped_at": "2026-01-10T07:51:44.067168",
  "sections": {
    "Administration": {
      "text": "Type: synthetic replacement for vasopressin\nDosage Forms:\ninjectable solution: 4 mcg/mL\ntablet: 0.1mg, 0.2mg\nnasal spray: 0.1mg/ mL (5mL); Delivers 10 mcg/spray, 1.5mg/mL (2.5mL); Delivers 150 mcg/spray\nRoutes of Administration: IV, IM, SC, intranasal, oral\nCommon Trade Names: DDAVP, Stimate",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Diabetes_Insipidus": {
          "text": "Intranasal: 10-40 mcg/day qday or divided q8-12 hr\nPO:\nInitial: 0.05mg q 12 hr\nEffective range: 0.1-1.2mg divided q 8-12 hr\nIV/SC: 2-4 mcg/day divided q12 hr or 1/10th the maintenance of intranasal dose",
          "tables": []
        },
        "Hemophilia_A_&_Von_Willebrand_Disease": {
          "text": "IV: 0.3 mcg/kg IV over 15-30 minutes IV (for pre-op 30 min before procedure)\nintranasal:\n<50 kg: 150 mcg; for pre-op, give 2 hr before procedure\n>50 kg: 300 mcg; for pre-op, give 2 hr before procedure",
          "tables": []
        },
        "Nocturnal_Enuresis": {
          "text": "0.2mgPO qHS (up to 0.6mg/day)",
          "tables": []
        },
        "Uremic_Bleeding_in_Acute_or_Chronic_Renal_Failure": {
          "text": "0.4 mcg/kg IV over 10 minutes",
          "tables": []
        },
        "DDAVP_Clamp": {
          "text": "Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water\n2 mcg IV q8h\n[1]",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Diabetes_Insipidus": {
      "text": "Intranasal: 10-40 mcg/day qday or divided q8-12 hr\nPO:\nInitial: 0.05mg q 12 hr\nEffective range: 0.1-1.2mg divided q 8-12 hr\nIV/SC: 2-4 mcg/day divided q12 hr or 1/10th the maintenance of intranasal dose",
      "subsections": {
        "Hemophilia_A_&_Von_Willebrand_Disease": {
          "text": "IV: 0.3 mcg/kg IV over 15-30 minutes IV (for pre-op 30 min before procedure)\nintranasal:\n<50 kg: 150 mcg; for pre-op, give 2 hr before procedure\n>50 kg: 300 mcg; for pre-op, give 2 hr before procedure",
          "tables": []
        },
        "Nocturnal_Enuresis": {
          "text": "0.2mgPO qHS (up to 0.6mg/day)",
          "tables": []
        },
        "Uremic_Bleeding_in_Acute_or_Chronic_Renal_Failure": {
          "text": "0.4 mcg/kg IV over 10 minutes",
          "tables": []
        },
        "DDAVP_Clamp": {
          "text": "Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water\n2 mcg IV q8h\n[1]",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hemophilia_A_&_Von_Willebrand_Disease": {
      "text": "IV: 0.3 mcg/kg IV over 15-30 minutes IV (for pre-op 30 min before procedure)\nintranasal:\n<50 kg: 150 mcg; for pre-op, give 2 hr before procedure\n>50 kg: 300 mcg; for pre-op, give 2 hr before procedure",
      "subsections": {
        "Nocturnal_Enuresis": {
          "text": "0.2mgPO qHS (up to 0.6mg/day)",
          "tables": []
        },
        "Uremic_Bleeding_in_Acute_or_Chronic_Renal_Failure": {
          "text": "0.4 mcg/kg IV over 10 minutes",
          "tables": []
        },
        "DDAVP_Clamp": {
          "text": "Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water\n2 mcg IV q8h\n[1]",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Nocturnal_Enuresis": {
      "text": "0.2mgPO qHS (up to 0.6mg/day)",
      "subsections": {
        "Uremic_Bleeding_in_Acute_or_Chronic_Renal_Failure": {
          "text": "0.4 mcg/kg IV over 10 minutes",
          "tables": []
        },
        "DDAVP_Clamp": {
          "text": "Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water\n2 mcg IV q8h\n[1]",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Uremic_Bleeding_in_Acute_or_Chronic_Renal_Failure": {
      "text": "0.4 mcg/kg IV over 10 minutes",
      "subsections": {
        "DDAVP_Clamp": {
          "text": "Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water\n2 mcg IV q8h\n[1]",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "DDAVP_Clamp": {
      "text": "Eliminate unpredictable excretion of water from kidneys by stimulating V2-vasopressin receptors in the kidney, causing renal retention of water\n2 mcg IV q8h\n[1]",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "",
      "subsections": {
        "3_months_to_12_years_(intranasal)": {
          "text": "5-30 mcg/day qday or divided q12 hr (using 100 mcg/mL solution)",
          "tables": []
        },
        ">12_years_(intranasal)": {
          "text": "10-40mcg/day qday or divided q12 hr (using 100 mcg/mL solution)",
          "tables": []
        },
        "3_months_to_12_years_(oral)": {
          "text": "Initial: 0.05mg q 12 hr\nEffective range: 0.1-1.2mg",
          "tables": []
        },
        ">12_years_(oral)": {
          "text": "Initial 0.05mg PO q 12 hr\nEffective range: 0.1-1.2mg divided q8-12 hr",
          "tables": []
        },
        "3_months_to_12_years_(IV/SC)": {
          "text": "0.1-1 mcg qday or divded q12 hr",
          "tables": []
        },
        ">12_years_(IV/SC)": {
          "text": "2-4 mcg/day divided q 12 hr or one tenth the maintenance of intranasal dose",
          "tables": []
        },
        "Nocturnal_Enuresis_2": {
          "text": ">6 years: 0.2mg PO qHS; up to 0.6mg/day",
          "tables": []
        },
        "Hemophilia_A_&_Von_Willebrand_Disease_2": {
          "text": "0.3 mcg/kg IV over 15-30 minutes; for pre-op, give 30 minutes before procedure\n1 spray (150 mcg) per nostril (300 mcg total dose) if >12 years of age or >50 kg body weight\nadminister single spray (150 mcg) if patient >12 years of age but <50 kg body weight\n(Fluid intake should be limited 1 hr prior to dose until the next morning or at least 8 hr after administration)",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Diabetes_Insipidus_2": {
      "text": "",
      "subsections": {
        "3_months_to_12_years_(intranasal)": {
          "text": "5-30 mcg/day qday or divided q12 hr (using 100 mcg/mL solution)",
          "tables": []
        },
        ">12_years_(intranasal)": {
          "text": "10-40mcg/day qday or divided q12 hr (using 100 mcg/mL solution)",
          "tables": []
        },
        "3_months_to_12_years_(oral)": {
          "text": "Initial: 0.05mg q 12 hr\nEffective range: 0.1-1.2mg",
          "tables": []
        },
        ">12_years_(oral)": {
          "text": "Initial 0.05mg PO q 12 hr\nEffective range: 0.1-1.2mg divided q8-12 hr",
          "tables": []
        },
        "3_months_to_12_years_(IV/SC)": {
          "text": "0.1-1 mcg qday or divded q12 hr",
          "tables": []
        },
        ">12_years_(IV/SC)": {
          "text": "2-4 mcg/day divided q 12 hr or one tenth the maintenance of intranasal dose",
          "tables": []
        },
        "Nocturnal_Enuresis_2": {
          "text": ">6 years: 0.2mg PO qHS; up to 0.6mg/day",
          "tables": []
        },
        "Hemophilia_A_&_Von_Willebrand_Disease_2": {
          "text": "0.3 mcg/kg IV over 15-30 minutes; for pre-op, give 30 minutes before procedure\n1 spray (150 mcg) per nostril (300 mcg total dose) if >12 years of age or >50 kg body weight\nadminister single spray (150 mcg) if patient >12 years of age but <50 kg body weight\n(Fluid intake should be limited 1 hr prior to dose until the next morning or at least 8 hr after administration)",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Nocturnal_Enuresis_2": {
      "text": ">6 years: 0.2mg PO qHS; up to 0.6mg/day",
      "subsections": {
        "Hemophilia_A_&_Von_Willebrand_Disease_2": {
          "text": "0.3 mcg/kg IV over 15-30 minutes; for pre-op, give 30 minutes before procedure\n1 spray (150 mcg) per nostril (300 mcg total dose) if >12 years of age or >50 kg body weight\nadminister single spray (150 mcg) if patient >12 years of age but <50 kg body weight\n(Fluid intake should be limited 1 hr prior to dose until the next morning or at least 8 hr after administration)",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hemophilia_A_&_Von_Willebrand_Disease_2": {
      "text": "0.3 mcg/kg IV over 15-30 minutes; for pre-op, give 30 minutes before procedure\n1 spray (150 mcg) per nostril (300 mcg total dose) if >12 years of age or >50 kg body weight\nadminister single spray (150 mcg) if patient >12 years of age but <50 kg body weight\n(Fluid intake should be limited 1 hr prior to dose until the next morning or at least 8 hr after administration)",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n:Pregnancy Category B\nLactation risk\n: minimally excreted in breast milk, acceptable to use",
      "subsections": {
        "Renal_Dosing": {
          "text": "CrCl <50 mL/min: Contraindicated; has been used unlabeled in acute and chronic renal failure patients experiencing uremic bleeding or prevention of surgical bleeding, limit to 1 dose\nCrCl ≥50 mL/min: No adjustments necessary",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Renal_Dosing": {
      "text": "CrCl <50 mL/min: Contraindicated; has been used unlabeled in acute and chronic renal failure patients experiencing uremic bleeding or prevention of surgical bleeding, limit to 1 dose\nCrCl ≥50 mL/min: No adjustments necessary",
      "subsections": {
        "Hepatic_Dosing": {
          "text": "not defined",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Hepatic_Dosing": {
      "text": "not defined",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug\npatients <3 months (hemophilia A or von Willebrand disease patients)\nCrCl <50\nvon Willebrand disease, type IIB\nhyponatremia",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Caution_to_use": {
      "text": "renal impairment\nfluid and electrolyte imbalance\npolydipsia\nelderly patients\nyoung children\ncystic fibrosis\ncoronary artery disease\nhypertension\nCongestive Heart Failure\nthrombosis risk",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "anaphylaxis\nrespiratory arrest\nhyponatremia\nwater intoxication\nseizures\nthrombosis",
          "tables": []
        },
        "Common": {
          "text": "flushing\nheadache\nrhinitis\nnausea\nabdominal pain\ndizziness\ncough\nepistaxis\nrigors\nconjunctivitis\nhypertension\nhypotension",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "anaphylaxis\nrespiratory arrest\nhyponatremia\nwater intoxication\nseizures\nthrombosis",
      "subsections": {
        "Common": {
          "text": "flushing\nheadache\nrhinitis\nnausea\nabdominal pain\ndizziness\ncough\nepistaxis\nrigors\nconjunctivitis\nhypertension\nhypotension",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "flushing\nheadache\nrhinitis\nnausea\nabdominal pain\ndizziness\ncough\nepistaxis\nrigors\nconjunctivitis\nhypertension\nhypotension",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 1.5 -2.5 hr (oral); 3 hr (IV)\nMetabolism: kidney; CYP 450\nExcretion: urine primarily",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "synthetic arginine vasopressin (antidiuretic hormone) analogue; exerts antidiuretic effects and increases plasma factor VIII and von Willebrand factor levels",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "References": {
      "text": "epocrates, medscape",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}